Society for Neuro-Oncology Annual Meeting 2021
Phase 2 clinical trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated GBM
Society for Neuro-Oncology Annual Meeting 2021
Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT unmethylated, bevacizumab naïve glioblastoma in the adjuvant or recurrent setting
American Association for Cancer Research Annual Meeting
Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the adjuvant or recurrent setting
American Association for Cancer Research Annual Meeting
Phase 2 study of dianhydrogalactitol (VAL-083) in patients with newly-diagnosed, MGMT-unmethylated glioblastoma
Society for Neuro-Oncology Annual Meeting 2020
Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting
Society for Neuro-Oncology Annual Meeting 2020
Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM
American Association for Cancer Research Virtual Annual Meeting II
Phase 2 study of dianhydrogalactitol (VAL-083) in patients with newly diagnosed, MGMT-unmethylated glioblastoma
American Association for Cancer Research Virtual Annual Meeting II
Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the adjuvant or recurrent setting